ARCHIVES

Ivax Paclitaxel To Remain On Market In Deal With BMS.

This article is from The Cancer Letter archive.

Vol. 28 No. 05 | February 1, 2002

Download PDF Visit The Full Archive

Related Articles

GAO Report: Taxol CRADA “Successful,” But Not Great Financial Deal.

June 27, 2003

Marijuana-Derived Drug Less Effective Than Standard

March 29, 2002

Adamson, Henney Chair Silicone Task Force

April 25, 1992

In Brief: FDA approves Three-Hour Taxol Infusion; Foti Elected President Of NCCR; Luce Retires

September 9, 1994

Clinical Cooperative Groups Asked To Develop Tamoxifen Prevention Trial; CGOPs To Participate

July 6, 1990

Harvard’s DePinho Becomes Finalist at MD Anderson

May 20, 2011